



MED-RA UPDATES

New Proposals and Awards Spotlight

Last month CoM faculty submitted 6 sponsored funding proposals. Please congratulate the faculty listed below for their awards during the month of September.

Dr. Angelina Sutin - U01 agreement award for \$3,751,505
 Dr. Mohamed Kabbaj - R01 grant for \$1,849,286
 Dr. David Meckes - R01 supplement for \$376,629



News and Notes

2018 Bayh-Dole Act: Inventions Resulting From NIH Funded Projects

The National Institutes of Health (NIH) has issued a notice regarding the 2018 Bayh-Dole Act, which relates to inventions resulting from NIH funded projects. [**NOT-OD-18-233**](#)

NIH & AHRQ Application Instruction and Review Criteria Updates

NIH has released a notice regarding upcoming updates to application instructions and review criteria for research grant applications. Changes relating to rigor, inclusion reporting, and protections for human subjects effective for applications submitted on or after January 25, 2019. [**NOT-OD-18-228**](#)

Upcoming Events

October 11– The Grand Rounds Research Symposium features presentations by select Summer Research Fellowship recipients. There will be a poster session from 12:00 pm - 12:50 pm and a lecture at 4:00 pm.

October 16 - Sponsored Research Administration's 4th Annual Open House. The event is from 2:00 pm - 4:00pm.

DEADLINES

*All proposal elements are due to our office ten (10) business days before the sponsor's deadline. This ensures Med-RA can secure all CoM approvals and help assemble the completed proposal for submission according to the University's requirement that all proposals be submitted for approval by three (3) working days prior to the agency deadline. [**More Information.**](#)*

NIH Standard Due Dates

Cycle 3 began on **September 25, 2018** and standard due dates for common mechanisms are as follows:

| Activity Code - NIH Deadline | Med-RA Deadline |
|--|------------------------|
| R03, R21, R33, R34, R36 (new) - October 16th | October 2 |
| R15 (all) - October 25th | October 11 |
| R01 (renewal, resubmissions, revisions) - November 5th | October 22 |
| K series (renewal, resubmissions, revisions) - November 13th | October 29 |
| R03, R21, R33, R34, R36 (renewal, resubmissions, revisions) - November 16th | November 1 |
| F series (all) - December 10th | November 26 |

FEATURED FUNDING OPPORTUNITIES

Children's Tumor Foundation Gene Therapy Initiative

The Children's Tumor Foundation is announcing the initiation of a research program in gene-based therapeutic approaches for the treatment of neurofibromatosis type 1 (NF1). Funding for each study will be \$240,000 total (inclusive of 10% indirect costs) for a duration of two years. The objective of this first goal is to support proof of principle in vitro studies to investigate the feasibility of genome editing techniques, including but not limited to those based on CRISPR-Cas9, to correct pathogenic mutations in NF1 gene. Experimental outcomes should include: (1) evidence indicating whether the editing reagents can correct the mutation(s) (and characterization of off-target effects), (2) degree of success in delivering the reagents to Schwann cells, and (3) a functional assay showing efficacy. The required letter of intent due **November 9, 2018**. [More information.](#)

Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)

This Funding Opportunity Announcement invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. **Standard dates apply. Expires January 8, 2022.** [More information.](#)

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 / R01 Clinical Trial Not Allowed)

The purpose of these Funding Opportunity Announcements (FOAs) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. Due **November 27, 2018; February 11, 2019; July 11, 2019; November 12, 2019.** [R21 information.](#) [R01 information.](#)

OTHER FUNDING RESOURCES

If you are interested in seeking funding, please visit our [webpage](#) for a link to all available resources and funding opportunities. You may also reach out directly to the Office of Research Administration by sending an [email](#). Med-RA staff are available to assist you and help locate appropriate grants pertaining to your field of interest.

TERRA'S TIPS

Finding funding opportunities—especially foundation opportunities—can be time consuming (and inbox crowding, if you subscribe to a number of foundation newsletters in hopes of keeping up with requests for proposals). My favorite source of foundation RFPs is [Philanthropy News Digest](#). In fact, I have collected dozens and dozens of such RFPs at my [funding opportunity blog](#). Feel free to [email me](#) or peruse my collection if you're interested in learning about RFPs you might be missing.

FUN STUFF

What is your favorite classic horror film?*

Click [here](#) to vote!

*Results from this month's survey will be posted in next month's newsletter and will be applied to an upcoming research event!



September Poll Results:

The CoM favorite dessert is **ICE CREAM!**

Quote of the Month:

"The art and science of asking questions is the source of all knowledge".

- Thomas Berger



Subscribing to the Med RA Newsletter

You received this newsletter either because you have subscribed to our ListServ or you are new faculty with research responsibility. To opt out of the ListServ, click [UNSUBSCRIBE](#). To be added to the ListServ, click [SUBSCRIBE](#).

Other Funding ListServes

SRA Listserv Administration — [More Information.](#)

FSU Office of Research Newsletter — [More Information.](#)